Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery

  1. Behavioral Research Program
  2. Events
  3. Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery
View this Webinar
Event Type:
Webinar
Date:
May 9, 2017

Webinar

Event Materials

Event Series

Notice of Funding Opportunity (NOFO) Webinars

View other webinars in this series.

These funding announcements have been reissued as PA-18-004 (R01 Clinical Trial Optional) and PA-18-014 (R21 Clinical Trial Optional).

This webinar provides an overview of the R01 and R21 funding opportunity announcements, Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery. The announcements have been reissued as PA-18-004 (R01 Clinical Trial Optional) and PA-18-014 (R21 Clinical Trial Optional).

Dr. Wendy Nelson and Ms. Kathleen Castro provide an overview of these funding opportunities that seek research to assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; identify structural, systemic, and psychosocial barriers to adherence; and develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized.

Speakers

Wendy Nelson, PhD, MPH
Wendy Nelson, PhD, MPH

Program Director,
Basic Biobehavioral and Psychological Sciences Branch,
Behavioral Research Program

Kelly Filipski, PhD, MPH
Kelly Filipski, PhD, MPH

Program Director,
Clinical and Translational Epidemiology Branch,
Epidemiology and Genomics Research Program

Kathleen Castro, RN, MS, AOCN®
Kathleen Castro, RN, MS, AOCN®

Program Director,
Office of the Associate Director,
Healthcare Delivery Research Program

Last Updated
March 16, 2022